Located 41 Montvale Ave. in Stoneham, the Tufts Medical Center Cancer Center provides complete care for oncology and hematology. We offer expert care in a comfortable patient-centered environment with on-site chemotherapy & infusion services and, just across the street, radiation therapy. Our services are offered on the:
The Tufts Medicine Cancer Center provides expert care in the community with a full range of services and treatments in a comfortable environment.
At the Women’s Wellness Center, we prioritize females and those who were assigned female at birth health. Our center makes it easy for you to get the cancer prevention, treatment, and follow-up care that you need. Our comprehensive services include a state-of-the-art Breast Health Center, gynecologic oncology services, genetic testing and assessment, specialized physical therapy appointments for breast cancer patients and a breast cancer survivorship clinic. You can trust our team of experts to provide you with high-quality care and support during every step of your journey.
Breast cancer (BC) is the leading cause of cancer and the second most common cause of cancer related mortality in the United States. Although the prognosis of patients with BC has greatly improved over the past few years, there are still many unanswered questions. There is growing interest in identifying markers for treatment de-escalation or intensification in early and advanced breast cancer as well as in ductal carcinoma in situ (DCIS). Additionally, there are well known differences in disease biology and outcomes in groups from diverse genetic ancestry.
Lowell General Hospital has delivered high-quality and compassionate care since 1891. Our 2 inpatient hospital campuses, Cancer Center, Heart and Vascular Center, 4 urgent care locations, affiliated physicians and outpatient facilities provide state-of-the-art technology and a full range of specialty services in the Merrimack Valley.
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
The purpose of this study is to compare the usual treatment approach (surgery followed by chemotherapy) to using chemotherapy followed by surgery and then more chemotherapy
This research is to determine the performance characteristics of a urine-based test for the detection of recurrent bladder cancer in low-grade patients who have been treated according to standard practice and are undergoing routine surveillance cystoscopy. The cystoscopy is regarded as the gold standard for determining recurrence of cancer. The Co-Principal Investigator at Tufts University has developed a urine-based monitoring test of bladder cancer, using imaging of the surface of cells extracted from the patients’ urine.
If you are a patient with acute or chronic pain that has not responded to conventional therapies, our pain management team is ready with the expertise to diagnose, treat and help you manage your pain. We believe in reducing and managing pain without relying on prescription medication whenever possible.
MelroseWakefield Hospital has expanded our joint venture partnership with Shields Health to include state-of-the-art PET/CT imaging services, increasing access to advanced radiological care in our communities. PET/CT imaging services have changed location from Montvale Ave to our office at 888 Main St., Wakefield now provided by Shields Health.
PET/CT services will be provided on Mondays from 7 a.m. to 5 p.m. at 888 Main St., Wakefield.
To schedule, please contact Shields PET/CT scheduling department: Call 1.866.258.4PET(4738)
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.
Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called folate receptor alpha (FRα). It is being developed as maintenance therapy for the treatment of subjects with recurrent platinum-sensitive, highgrade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy).
